Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (67 quarters reported)
$281M in Q4 2009 → $1.72B now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Edgewise Therapeutics Inc | 12.6% | Unchanged | 5,350,000 | $217M |
| AH Asml Holding N V | 11.0% | Unchanged | 94,946 | $189M |
| HT Hemab Therapeutics Hldgs Inc | 8.9% | New | 4,180,550 | $154M |
| Brookfield Corp | 8.7% | Unchanged | 3,496,245 | $150M |
| Maplight Therapeutics Inc | 7.7% | Unchanged | 3,686,622 | $132M |
| Mirum Pharmaceuticals Inc | 7.6% | Trimmed 15% | 1,125,000 | $132M |
| AP Avalyn Pharmaceuticals Inc | 7.4% | New | 3,883,289 | $128M |
| Salesforce Inc | 3.6% | Unchanged | 393,187 | $61.6M |
| Arrivent Biopharma Inc | 3.0% | Trimmed 23% | 1,500,000 | $52.1M |
| Enliven Therapeutics Inc | 2.9% | Trimmed 22% | 1,000,000 | $50.8M |
| CP Crinetics Pharmaceuticals In | 2.9% | Trimmed 15% | 1,320,000 | $49.4M |
| Pharvaris N V | 2.8% | Trimmed 20% | 1,400,000 | $48.4M |
| F& Floor & Decor Hldgs Inc | 2.7% | New | 797,000 | $47.3M |
| Vaxcyte Inc | 2.7% | Trimmed 7.0% | 800,000 | $46.5M |
| 4M 4d Molecular Therapeutics In | 2.5% | Trimmed 11% | 3,249,178 | $43.2M |
| VT Viridian Therapeutics Inc | 2.3% | Added 6.8% | 2,135,000 | $39.2M |
| CT Celldex Therapeutics Inc New | 2.2% | Trimmed 15% | 1,025,000 | $38.1M |
| Alumis Inc | 1.8% | New | 1,100,000 | $31M |
| Xenon Pharmaceuticals Inc | 1.7% | Unchanged | 485,438 | $29.3M |
| AG Alibaba Group Hldg Ltd | 1.4% | Unchanged | 257,327 | $24.7M |
| Dyne Therapeutics Inc | 1.2% | New | 960,394 | $21.3M |
| BO Bridgebio Oncology Therapeut | 1.0% | Added 2.9% | 2,250,000 | $17.1M |
| Insmed Inc | 0.7% | New | 120,723 | $12.9M |
| Marqeta Inc | 0.4% | Unchanged | 441,558 | $7.17M |
| Lanzatech Global Inc | 0.1% | Unchanged | 158,148 | $1.08M |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended June 30, 2026 · filed August 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| HT Hemab Therapeutics Hldgs Inc | New | +4,180,550 | +$154M | 8.9% |
| AP Avalyn Pharmaceuticals Inc | New | +3,883,289 | +$128M | 7.4% |
| F& Floor & Decor Hldgs Inc | New | +797,000 | +$47.3M | 2.7% |
| Apogee Therapeutics Inc | Exited | −450,000 | −$37.9M | — |
| Biomarin Pharmaceutical Inc | Exited | −660,000 | −$37.3M | — |
| Alumis Inc | New | +1,100,000 | +$31M | 1.8% |
| Mirum Pharmaceuticals Inc | Trimmed | −200,000 | −$23.4M | 7.6% |
| Dyne Therapeutics Inc | New | +960,394 | +$21.3M | 1.2% |
| Arrivent Biopharma Inc | Trimmed | −442,142 | −$15.4M | 3.0% |
| Enliven Therapeutics Inc | Trimmed | −280,000 | −$14.2M | 2.9% |
Showing the 10 largest of 19 changes.
quarter ended March 31, 2026 · filed May 15, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Zenas Biopharma Inc | Exited | −1,450,000 | −$52.6M | — |
| Insmed Inc | Exited | −200,000 | −$34.8M | — |
| Xenon Pharmaceuticals Inc | New | +485,438 | +$28.2M | 2.3% |
| AH Asml Holding N V | Trimmed | −19,000 | −$25.1M | 10.2% |
| Salesforce Inc | Added | +63,000 | +$11.8M | 5.9% |
| Apogee Therapeutics Inc | Trimmed | −120,000 | −$10.1M | 3.1% |
| Enliven Therapeutics Inc | Trimmed | −200,000 | −$7.84M | 4.1% |
| Valneva Se | Trimmed | −1,247,579 | −$7.8M | 0.5% |
| VT Viridian Therapeutics Inc | Trimmed | −380,000 | −$7.43M | 3.2% |
| Mirum Pharmaceuticals Inc | Added | +60,972 | +$5.63M | 9.9% |
Showing the 10 largest of 14 changes.
quarter ended December 31, 2025 · filed February 17, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| VI Vanguard Index Fds | Exited | −1,038,550 | −$341M | — |
| Merus N V | Exited | −750,000 | −$70.6M | — |
| Maplight Therapeutics Inc | New | +3,686,622 | +$64.8M | 5.0% |
| Brookfield Corp | Added | +1,165,415 | +$53.5M | 12.5% |
| RP Recursion Pharmaceuticals In | Exited | −7,929,835 | −$38.7M | — |
| AH Asml Holding N V | Trimmed | −31,890 | −$34.1M | 9.5% |
| Zenas Biopharma Inc | Trimmed | −550,000 | −$20M | 4.1% |
| 4M 4d Molecular Therapeutics In | Added | +1,650,737 | +$12.4M | 2.1% |
| Apogee Therapeutics Inc | Added | +70,000 | +$5.28M | 3.3% |
| Enliven Therapeutics Inc | Added | +53,740 | +$828K | 1.8% |
Showing the 10 largest of 12 changes.
quarter ended September 30, 2025 · filed November 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Insmed Inc | Trimmed | −480,000 | −$69.1M | 1.9% |
| Blueprint Medicines Corp | Exited | −264,956 | −$34M | — |
| BO Bridgebio Oncology Therapeut | New | +1,961,317 | +$22.7M | 1.5% |
| AG Alibaba Group Hldg Ltd | Trimmed | −115,000 | −$20.6M | 3.0% |
| AH Asml Holding N V | Trimmed | −20,000 | −$19.4M | 9.1% |
| Mirum Pharmaceuticals Inc | Trimmed | −236,027 | −$17.3M | 6.0% |
| Ceribell Inc | Exited | −900,000 | −$16.9M | — |
| RP Recursion Pharmaceuticals In | Trimmed | −1,735,293 | −$8.47M | 2.5% |
| Enliven Therapeutics Inc | Added | +341,828 | +$7M | 1.9% |
| Zenas Biopharma Inc | Trimmed | −250,000 | −$5.55M | 2.9% |
Showing the 10 largest of 20 changes.
quarter ended June 30, 2025 · filed August 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Amicus Therapeutics Inc | Exited | −2,750,000 | −$22.4M | — |
| Enliven Therapeutics Inc | New | +1,084,432 | +$21.8M | 1.5% |
| Apogee Therapeutics Inc | New | +449,392 | +$19.5M | 1.4% |
| Salesforce Inc | Added | +57,386 | +$15.6M | 6.4% |
| Verve Therapeutics Inc | Exited | −3,000,000 | −$13.7M | — |
| Valneva Se | New | +2,375,000 | +$13.5M | 1.0% |
| Biomarin Pharmaceutical Inc | Added | +170,000 | +$9.34M | 2.6% |
| CP Crinetics Pharmaceuticals In | Added | +275,000 | +$7.91M | 3.1% |
| Rocket Pharmaceuticals Inc | Exited | −1,100,000 | −$7.34M | — |
| Blueprint Medicines Corp | Added | +36,152 | +$4.63M | 2.4% |
Showing the 10 largest of 21 changes.
quarter ended March 31, 2025 · filed May 15, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Tempus Ai Inc | Exited | −4,074,419 | −$138M | — |
| Brookfield Corp | Trimmed | −468,000 | −$24.5M | 9.3% |
| Cargo Therapeutics Inc | Exited | −1,663,724 | −$24M | — |
| Ceribell Inc | Added | +551,191 | +$10.6M | 1.3% |
| AG Alibaba Group Hldg Ltd | Trimmed | −80,000 | −$10.6M | 3.7% |
| CP Crinetics Pharmaceuticals In | Added | +314,785 | +$10.6M | 3.3% |
| Edgewise Therapeutics Inc | Added | +350,000 | +$7.7M | 9.0% |
| Arrivent Biopharma Inc | Added | +351,515 | +$6.5M | 2.6% |
| Vaxcyte Inc | Added | +165,000 | +$6.23M | 2.6% |
| Mersana Therapeutics Inc. | Exited | −4,250,000 | −$6.08M | — |
Showing the 10 largest of 20 changes.
quarter ended December 31, 2024 · filed February 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Corcept Therapeutics Inc | Exited | −2,411,362 | −$112M | — |
| RP Recursion Pharmaceuticals In | New | +10,114,633 | +$68.4M | 4.1% |
| Cable One Inc | Exited | −118,403 | −$41.4M | — |
| Brookfield Corp | Trimmed | −692,400 | −$39.8M | 9.7% |
| Alnylam Pharmaceuticals Inc | Exited | −118,383 | −$32.6M | — |
| BA Brookfield Asset Managmt Ltd | Exited | −627,207 | −$29.7M | — |
| Salesforce Inc | Trimmed | −74,659 | −$25M | 5.9% |
| AH Asml Holding N V | Added | +32,500 | +$22.5M | 7.0% |
| Edgewise Therapeutics Inc | Trimmed | −549,900 | −$14.7M | 8.1% |
| Ceribell Inc. | New | +328,809 | +$8.51M | 0.5% |
Showing the 10 largest of 21 changes.
quarter ended September 30, 2024 · filed October 24, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Apple Inc | Exited | −182,960 | −$38.5M | — |
| Salesforce Inc | Trimmed | −111,600 | −$30.5M | 5.0% |
| Vaxcyte Inc | Trimmed | −200,000 | −$22.9M | 4.3% |
| Edgewise Therapeutics Inc | Trimmed | −794,530 | −$21.2M | 7.4% |
| Brookfield Corp | Trimmed | −389,000 | −$20.7M | 9.2% |
| Zenas Biopharma Inc | New | +1,150,000 | +$19.5M | 1.0% |
| MH Morphic Hldg Inc | Exited | −375,000 | −$12.8M | — |
| VT Viridian Therapeutics Inc | Added | +385,000 | +$8.76M | 2.7% |
| Insmed Inc | Trimmed | −75,334 | −$5.5M | 2.6% |
| CT Celldex Therapeutics Inc New | Added | +113,663 | +$3.86M | 1.6% |
Showing the 10 largest of 18 changes.
Loading...
